Compare · MDGL vs NVO
MDGL vs NVO
Side-by-side comparison of Madrigal Pharmaceuticals Inc. (MDGL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDGL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 17.5x MDGL ($12.76B).
- Over the past year, MDGL is up 65.7% and NVO is down 21.8% - MDGL leads by 87.5 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 22 for MDGL).
- Company
- Madrigal Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $553.33+1.41%
- $50.31-2.25%
- Market cap
- $12.76B
- $222.81B
- 1M return
- +10.36%
- +15.47%
- 1Y return
- +65.69%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 5
- 5
- Recent ratings
- 22
- 25
Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MDGL
- Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
- Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Director Taub Rebecca was granted 454 shares, increasing direct ownership by 0.10% to 452,667 units (SEC Form 4)
- Director Levy Richard S was granted 454 shares, increasing direct ownership by 2% to 22,469 units (SEC Form 4)
- Director Fouse Jacqualyn A was granted 454 shares, increasing direct ownership by 41% to 1,551 units (SEC Form 4)
- Director Daly James M was granted 454 shares, increasing direct ownership by 17% to 3,081 units (SEC Form 4)
- Director Brennan Daniel J. was granted 404 shares, increasing direct ownership by 42% to 1,371 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S